Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High-dose peretinoin as adjunctive therapy in hepatitis C-positive patients with hepatocellular carcinoma following curative therapy (surgical resection or transcutaneous radiofrequency ablation).

Trial Profile

High-dose peretinoin as adjunctive therapy in hepatitis C-positive patients with hepatocellular carcinoma following curative therapy (surgical resection or transcutaneous radiofrequency ablation).

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peretinoin (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2011 New source identified and integrated: University Hospital Medical Information Network - Japan record UMIN000006728.
    • 24 Jan 2011 Results from a subgroup analysis presented at the ASCO Gastrointestinal Cancers Symposium in January 2011 (abstract 165), and reported in a Kowa Pharmaceutical media release.
    • 20 Jan 2011 Results of subanalysis to be presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011, according to a Kowa media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top